Point-of-Care Testing (POCT) Platform

Beijing, China

SynsorBio was founded in June 2020. We integrate R&D, manufacture, and sales of diagnostic reagents, NGS products and instruments. We use CRISPR as a core technology, with the combination of Microfluidics and Synthetic biology, to focus on the original R&D of emerging molecular biological techniques, together with R&D and applications of Point-of-care testing (POCT). We have obtained the authorization of CRISPR/Cas detection, which have already been industrialized into products. Moreover, we have also launched products related to NGS sample preparation, to meet the various needs of our customers. The R&D center is located in VPark in Beijing Economic and Technological Development Area, with an R&D and operation center covering an area of nearly 1,000 m 2 . At the same time, a modern integrated base including R&D, production and service has been built in Shaoxing, Zhejiang Province, with supporting production, logistics and service systems to ensure the strategic layout and business development needs. The company mainly engages in research of CRISPR-based diagnostic technology, microfluidics chip, and molecular POCT. The customers include hospitals, IVD companies, and medical laboratories, etc.